Deaths Linked to Vasculitis Drug Put Kissei in a Bind: Licensed-In Medicine, Locked-Out Data

The vasculitis treatment Tavneos faces multiple reported deaths and data-manipulation allegations at its original developer, with Western regulators moving toward withdrawing approval — while Kissei Pharmaceutical, which holds Japanese sales rights, says it has not been told the details. The episode exposes the structural weakness of the license-in model on which Japan's mid-sized drugmakers depend: the seller bears the safety responsibility while someone else holds the critical data. Every licensing-dependent pharma company now faces the same stress test — how deep due diligence must go, what data-access rights contracts must guarantee, and how liability lands when things explode. For investors in mid-cap pharma, the immediate homework is checking licensed-product exposure and contract transparency in their holdings. Beyond patient welfare, this is an expensive seminar in corporate governance.